Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Q2 2021 Halozyme Therapeutics Inc Earnings Call Transcript

Aug 09, 2021 / 08:30PM GMT
Release Date Price: €34.22 (+0.59%)
Operator

Thank you all for standing by, and welcome to the Halozyme Second Quarter 2021 Financial Results Conference Call. (Operator Instructions) Please also note that today's call is being recorded.

I'll now turn the call over to your host, Al Kildani. Sir, you may now begin.

Albert S. Kildani
Halozyme Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you. Good afternoon, and welcome to our Second Quarter 2021 Financial Results Conference Call. In addition to our press release issued today after the close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Elaine Sun, our Chief Financial Officer, who will review our financial results for the second quarter.

On today's call, both GAAP and non-GAAP financial measures will be discussed. The non-GAAP or adjusted financial measures are reconciled

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot